Understanding Oncotype DX
A genomic test that can help guide chemotherapy decisions
The short version
Oncotype DX is a genomic test that examines a group of genes within tumor tissue, producing a recurrence score that can help estimate whether chemotherapy is likely to add benefit for some early-stage, hormone-receptor-positive cancers.
Oncotype DX is a genomic test performed on tumor tissue that examines the activity of a group of genes. It produces a recurrence score, which can help estimate the likelihood of cancer returning and whether chemotherapy is likely to add meaningful benefit for some early-stage, hormone-receptor-positive, HER2-negative cancers.
This test is not appropriate or available for every diagnosis — your care team can explain whether it applies to your specific situation.
Questions you may want to ask
Am I a candidate for this or a similar genomic test?
How would the result change your treatment recommendation?